Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Details

vida: extract claims from 2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024

- Source: inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md
- Domain: health
- Claims: 2, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

2026-05-08 08:35:15 +00:00

2.3 KiB

Raw Blame History

LIXIPARK Trial

Type: Phase 2 randomized controlled trial
Indication: Early Parkinson's disease
Drug: Lixisenatide (GLP-1 receptor agonist)
Status: Completed, published NEJM April 2024
Primary endpoint: MDS-UPDRS Part III motor score at 12 months — MET

Design

N: 156 patients (75 lixisenatide, 75 placebo; some sources report 150)
Population: Early Parkinson's disease (<3 years since diagnosis)
Duration: 12 months
Design: Double-blind, placebo-controlled
Administration: Daily subcutaneous injection

Results

Primary endpoint (12 months):

Placebo group: MDS-UPDRS Part III worsened by +3.04 points (disease progression)
Lixisenatide group: Remained at baseline (0 change)
Between-group difference: Statistically significant
Interpretation: Lixisenatide halted motor symptom progression over 12 months

Safety:

50% of lixisenatide patients reported significant GI side effects (nausea, vomiting)
1/3 required dose reduction due to GI tolerability
Safety profile is a major practical concern for real-world implementation

Limitations

Phase 2 (not Phase 3 — not definitive)
12 months (shorter than exenatide Phase 3 at 96 weeks)
No DaT-SPECT brain imaging to confirm neuroprotection vs. symptomatic benefit
Off-label use NOT recommended pending Phase 3 confirmation

Context

Preliminary results presented at 2023 International Parkinson and Movement Disorder Society congress (Copenhagen)
Published NEJM April 2024
As of May 2026, no Phase 3 funding announced despite positive Phase 2 result
Contrasts with exenatide Phase 3 failure (Lancet February 2025)

Mechanistic hypothesis

Lixisenatide crosses BBB via adsorption transcytosis (Holscher 2024). Holscher identifies lixisenatide as having "strongest neuroprotective effect" among GLP-1 agonists in clinical trials, correlating with BBB penetrance mechanism. The divergence from exenatide suggests regional CNS penetrance (specifically substantia nigra) may determine efficacy.

Timeline

2023 — Preliminary results presented at International Parkinson and Movement Disorder Society congress, Copenhagen
2024-04-04 — Full results published in New England Journal of Medicine
2026-05 — No Phase 3 funding announced; exenatide Phase 3 failure may have chilled further GLP-1 Parkinson's investment

2.3 KiB Raw Blame History